The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial.
BACKGROUND: The intra-tumor stroma percentage in colon cancer (CC) patients has previously been reported by our group as a strong independent prognostic parameter. Patients with a high stroma percentage within the primary tumor have a poor prognosis. PATIENTS AND METHODS: Tissue samples from the mo...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2013
|
| _version_ | 1797059190683860992 |
|---|---|
| author | Huijbers, A Tollenaar, R v Pelt, G Zeestraten, E Dutton, S McConkey, C Domingo, E Smit, V Midgley, R Warren, B Johnstone, E Kerr, D Mesker, W |
| author_facet | Huijbers, A Tollenaar, R v Pelt, G Zeestraten, E Dutton, S McConkey, C Domingo, E Smit, V Midgley, R Warren, B Johnstone, E Kerr, D Mesker, W |
| author_sort | Huijbers, A |
| collection | OXFORD |
| description | BACKGROUND: The intra-tumor stroma percentage in colon cancer (CC) patients has previously been reported by our group as a strong independent prognostic parameter. Patients with a high stroma percentage within the primary tumor have a poor prognosis. PATIENTS AND METHODS: Tissue samples from the most invasive part of the primary tumor of 710 patients (52% Stage II, 48% Stage III) participating in the VICTOR trial were analyzed for their tumor-stroma percentage. Stroma-high (>50%) and stroma-low (≤50%) groups were evaluated with respect to survival times. RESULTS: Overall and disease-free survival times (OS and DFS) were significantly lower in the stroma-high group (OS P<0.0001, hazard ratio (HR)=1.96; DFS P<0.0001, HR=2.15). The 5-year OS was 69.0% versus 83.4% and DFS 58.6% versus 77.3% for stroma-high versus stroma-low patients. CONCLUSION: This study confirms the intra-tumor stroma ratio as a prognostic factor. This parameter could be a valuable and low cost addition to the TNM status and next to current high-risk parameters such as microsatellite instability status used in routine pathology reporting. When adding the stroma-parameter to the ASCO criteria, the rate of 'undertreated' patients dropped from 5.9% to 4.3%, the 'overtreated' increased with 6.8% but the correctly classified increased with an additional 14%. |
| first_indexed | 2024-03-06T20:00:41Z |
| format | Journal article |
| id | oxford-uuid:27316de1-fe96-4afc-9127-11c46ff14ec7 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T20:00:41Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | oxford-uuid:27316de1-fe96-4afc-9127-11c46ff14ec72022-03-26T12:05:31ZThe proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:27316de1-fe96-4afc-9127-11c46ff14ec7EnglishSymplectic Elements at Oxford2013Huijbers, ATollenaar, Rv Pelt, GZeestraten, EDutton, SMcConkey, CDomingo, ESmit, VMidgley, RWarren, BJohnstone, EKerr, DMesker, W BACKGROUND: The intra-tumor stroma percentage in colon cancer (CC) patients has previously been reported by our group as a strong independent prognostic parameter. Patients with a high stroma percentage within the primary tumor have a poor prognosis. PATIENTS AND METHODS: Tissue samples from the most invasive part of the primary tumor of 710 patients (52% Stage II, 48% Stage III) participating in the VICTOR trial were analyzed for their tumor-stroma percentage. Stroma-high (>50%) and stroma-low (≤50%) groups were evaluated with respect to survival times. RESULTS: Overall and disease-free survival times (OS and DFS) were significantly lower in the stroma-high group (OS P<0.0001, hazard ratio (HR)=1.96; DFS P<0.0001, HR=2.15). The 5-year OS was 69.0% versus 83.4% and DFS 58.6% versus 77.3% for stroma-high versus stroma-low patients. CONCLUSION: This study confirms the intra-tumor stroma ratio as a prognostic factor. This parameter could be a valuable and low cost addition to the TNM status and next to current high-risk parameters such as microsatellite instability status used in routine pathology reporting. When adding the stroma-parameter to the ASCO criteria, the rate of 'undertreated' patients dropped from 5.9% to 4.3%, the 'overtreated' increased with 6.8% but the correctly classified increased with an additional 14%. |
| spellingShingle | Huijbers, A Tollenaar, R v Pelt, G Zeestraten, E Dutton, S McConkey, C Domingo, E Smit, V Midgley, R Warren, B Johnstone, E Kerr, D Mesker, W The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. |
| title | The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. |
| title_full | The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. |
| title_fullStr | The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. |
| title_full_unstemmed | The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. |
| title_short | The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. |
| title_sort | proportion of tumor stroma as a strong prognosticator for stage ii and iii colon cancer patients validation in the victor trial |
| work_keys_str_mv | AT huijbersa theproportionoftumorstromaasastrongprognosticatorforstageiiandiiicoloncancerpatientsvalidationinthevictortrial AT tollenaarr theproportionoftumorstromaasastrongprognosticatorforstageiiandiiicoloncancerpatientsvalidationinthevictortrial AT vpeltg theproportionoftumorstromaasastrongprognosticatorforstageiiandiiicoloncancerpatientsvalidationinthevictortrial AT zeestratene theproportionoftumorstromaasastrongprognosticatorforstageiiandiiicoloncancerpatientsvalidationinthevictortrial AT duttons theproportionoftumorstromaasastrongprognosticatorforstageiiandiiicoloncancerpatientsvalidationinthevictortrial AT mcconkeyc theproportionoftumorstromaasastrongprognosticatorforstageiiandiiicoloncancerpatientsvalidationinthevictortrial AT domingoe theproportionoftumorstromaasastrongprognosticatorforstageiiandiiicoloncancerpatientsvalidationinthevictortrial AT smitv theproportionoftumorstromaasastrongprognosticatorforstageiiandiiicoloncancerpatientsvalidationinthevictortrial AT midgleyr theproportionoftumorstromaasastrongprognosticatorforstageiiandiiicoloncancerpatientsvalidationinthevictortrial AT warrenb theproportionoftumorstromaasastrongprognosticatorforstageiiandiiicoloncancerpatientsvalidationinthevictortrial AT johnstonee theproportionoftumorstromaasastrongprognosticatorforstageiiandiiicoloncancerpatientsvalidationinthevictortrial AT kerrd theproportionoftumorstromaasastrongprognosticatorforstageiiandiiicoloncancerpatientsvalidationinthevictortrial AT meskerw theproportionoftumorstromaasastrongprognosticatorforstageiiandiiicoloncancerpatientsvalidationinthevictortrial AT huijbersa proportionoftumorstromaasastrongprognosticatorforstageiiandiiicoloncancerpatientsvalidationinthevictortrial AT tollenaarr proportionoftumorstromaasastrongprognosticatorforstageiiandiiicoloncancerpatientsvalidationinthevictortrial AT vpeltg proportionoftumorstromaasastrongprognosticatorforstageiiandiiicoloncancerpatientsvalidationinthevictortrial AT zeestratene proportionoftumorstromaasastrongprognosticatorforstageiiandiiicoloncancerpatientsvalidationinthevictortrial AT duttons proportionoftumorstromaasastrongprognosticatorforstageiiandiiicoloncancerpatientsvalidationinthevictortrial AT mcconkeyc proportionoftumorstromaasastrongprognosticatorforstageiiandiiicoloncancerpatientsvalidationinthevictortrial AT domingoe proportionoftumorstromaasastrongprognosticatorforstageiiandiiicoloncancerpatientsvalidationinthevictortrial AT smitv proportionoftumorstromaasastrongprognosticatorforstageiiandiiicoloncancerpatientsvalidationinthevictortrial AT midgleyr proportionoftumorstromaasastrongprognosticatorforstageiiandiiicoloncancerpatientsvalidationinthevictortrial AT warrenb proportionoftumorstromaasastrongprognosticatorforstageiiandiiicoloncancerpatientsvalidationinthevictortrial AT johnstonee proportionoftumorstromaasastrongprognosticatorforstageiiandiiicoloncancerpatientsvalidationinthevictortrial AT kerrd proportionoftumorstromaasastrongprognosticatorforstageiiandiiicoloncancerpatientsvalidationinthevictortrial AT meskerw proportionoftumorstromaasastrongprognosticatorforstageiiandiiicoloncancerpatientsvalidationinthevictortrial |